墨西哥茶苯海明市场 – 行业趋势和 2029 年预测

市场分析与洞察 ：墨西哥茶苯海明市场

墨西哥茶苯海明市场预计将在 2022 年至 2029 年的预测期内获得显着增长。Data Bridge Market Research 分析，在 2022 年至 2029 年的预测期内，该市场的复合年增长率为 2.4%，预计到 2029 年将达到 1,054.36 万美元。晕动病和过敏发病率的上升预计将推动墨西哥茶苯海明市场的增长。

茶苯海明是一种抗组胺药，用于避免和治疗儿童和成人因晕动病引起的头晕、恶心和呕吐。茶苯海明属于一类称为抗组胺药的药物。它通过预防身体平衡问题发挥作用。茶苯海明是一种抗组胺药，可减少体内的天然化学组胺。第一剂应在旅行或开始任何活动前 30 分钟至 1 小时服用，以避免晕动病。茶苯海明以乘晕药、晕车药和 gravol 的名称销售。这些茶苯海明的商品名称被用作非处方药。有时，茶苯海明也用于治疗梅尼埃病（一种导致极度头晕、失去平衡和听力丧失的内耳疾病）和其他内耳问题。

墨西哥人口中恶心、呕吐和过敏的患病率不断上升，这可能会推动墨西哥茶苯海明市场的增长。与茶苯海明药物相关的不良反应可能会阻碍市场的增长。人们对其作为非处方药的使用意识可以为促进市场需求创造机会。使用新型疗法治疗恶心可能会对墨西哥茶苯海明市场的增长构成挑战。

墨西哥茶苯海明市场报告提供了市场份额、新发展和产品线分析、国内和本地市场参与者的影响的详细信息，分析了新兴收入领域、市场法规变化、产品批准、战略决策、产品发布、地域扩张和市场技术创新方面的机会。要了解分析和市场情景，请联系我们获取分析师简报；我们的团队将帮助您创建收入影响解决方案，以实现您的期望目标。

墨西哥茶苯海明 市场范围和市场规模

The Mexico dimenhydrinate market is categorized into seven segments based on prescription type, application, route of administration, dosage form, product type, age, and distribution channel.

• On the basis of prescription type, the Mexico dimenhydrinate market is segmented into over-the-counter (OTC), and prescription drugs. In 2022, the over-the-counter (OTC) segment is expected to dominate the market since there are no specific laws for the use of OTC medications and the ability to invest in medium-scale companies in Mexico, which manufacture and supply dimenhydrinate. The brands available for our market-focused product in Mexico are OTC drugs.
• On the basis of application, the Mexico dimenhydrinate market is segmented into nausea, vomiting, dizziness, insomnia, allergies, and others. In 2022, the nausea segment is expected to dominate the Mexico dimenhydrinate market due to the rise in the geriatric population in Mexico suffering from motion sickness and increased awareness of treatment of motion sickness.
• On the basis of route of administration, the Mexico dimenhydrinate market is segmented into oral and parenteral. In 2022, the oral segment is expected to dominate the Mexico dimenhydrinate market as most of the drugs offered in the market are oral tablets due to their ease of absorption and availability.
• On the basis of dosage form, the Mexico dimenhydrinate market is segmented into tablets, chewables, syrup, injections, and others. In 2022, the tablets segment is expected to dominate the Mexico dimenhydrinate market since it is widely available and easy to absorb.
• On the basis of product type, the Mexico dimenhydrinate market is segmented into branded and generic. In 2022, the branded segment is expected to dominate the Mexico dimenhydrinate market, as most of the branded drugs offered by the companies are originally submitted by the Food and Drug Administration (FDA) and Federal Commission for the Protection against Sanitary Risk (COFEPRIS) and are highly used by consumers.
• On the basis of age group, the Mexico dimenhydrinate market is segmented into adult, geriatric, and child. In 2022, the adult segment is expected to dominate the Mexico dimenhydrinate market due to a rise in cases of nausea and dizziness cases among adults.
• On the basis of distribution channel, the Mexico dimenhydrinate market is segmented into store based retail and online based retail. In 2022, the store based retail segment is expected to dominate the Mexico dimenhydrinate market due to increased interaction with certified prescribers and health professionals for the use of anti-depressants and guaranteed payment.

Growing strategic activities by major market players to enhance awareness of dimenhydrinate to boost the market growth

墨西哥茶苯海明市场还提供了每个国家在特定市场增长的详细市场分析。此外，它还提供了有关市场参与者的战略和地理分布的详细信息。数据适用于 2011 年至 2020 年的历史时期。

竞争格局和墨西哥茶苯海明市场份额分析

墨西哥茶苯海明市场竞争格局提供了竞争对手的详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、生产基地和设施、公司优势和劣势、产品发布、产品试验渠道、产品批准、专利、产品宽度和广度、应用优势、技术生命线曲线。以上提供的数据点仅与公司对墨西哥茶苯海明市场的关注有关

墨西哥茶苯海明市场的主要参与者包括 Johnson & Johnson SA de CV、Prestige Consumer Healthcare Inc. 和 CINFA LABORATORIES（Mundipharma 的子公司）等。DBMR 分析师了解竞争优势，并为每个竞争对手分别提供竞争分析。

世界各地的公司也签订了许多合同和协议，进一步加速了墨西哥茶苯海明市场的增长。

例如，

• 2021 年 7 月，Prestige Consumer Healthcare 宣布已完成对 TheraTears 和其他非处方消费品牌的收购。此举有望增加该公司在美国的生产能力并有助于增加收入。

SKU-67782